Background: Patients with hematologic malignancies are associated with a high incidence of invasive candidiasis and a high risk of mortality. Azoles are the only antifungal prophylactic agents. Echinocandins are novel antifungal agents with antifungal activity against most isolates of Candida species and Aspergillus species.
Objectives: The aim of this trial was to evaluate the effect of echinocandin for the prevention of invasive candidiasis in patients with hematologic malignancies.
Methods: The following databases were searched: MEDLINE; Pubmed and Cochrane databases. Interventions included echinocandin for patients with hematologic malignancies. The search to identify relevant randomized controlled trials (RCTs). Statistical analysis was performed with Review Manager Version 5.3.
Results: We included five RCTs and 1632 participants. We pooled results from five studies. For the overall incidence of invasive fungal infections there was no significant difference between echinocandins and azoles (risk ratio 0.84, 95% confidence interval 0.71 to 1.01).
Conclusions: This meta-analysis shows that the efficacy of echinocandins is similar to that of azoles when used in prophylactic regimens. Echinocandins could be another type of prophylactic antifungal agent for patients with hematologic malignancies.